Zoya N Demidenko
Overview
Explore the profile of Zoya N Demidenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Demidenko Z, Shtutman M, Blagosklonny M
Cell Cycle
. 2009 May;
8(12):1896-900.
PMID: 19478560
Inhibition of mTOR by rapamycin prevents cellular senescence. Here we investigated the effects of MEK and PI-3K on cellular senescence. Unlike LY294002 (PI-3K inhibitor), both U0126 and PD98059 (MEK inhibitors)...
22.
Demidenko Z, Blagosklonny M
Cell Cycle
. 2009 May;
8(12):1901-4.
PMID: 19471118
Here we demonstrated that, at cytostatic, near-toxic concentrations, resveratrol inhibited S6 phosphorylation and prevented the senescence morphology in human cells. Using a sensitive functional assay, we found that resveratrol partially...
23.
Demidenko Z, Zubova S, Bukreeva E, Pospelov V, Pospelova T, Blagosklonny M
Cell Cycle
. 2009 May;
8(12):1888-95.
PMID: 19471117
When the cell cycle is arrested but cellular growth is not, then cells senesce, permanently losing proliferative potential. Here we demonstrated that the duration of cell cycle arrest determines a...
24.
Demidenko Z, Blagosklonny M
Cell Cycle
. 2008 Oct;
7(21):3355-61.
PMID: 18948731
We tested a hypothesis that activation of growth-promoting pathways is required for cellular senescence. In the presence of serum, induction of p21 caused senescence, characterized by beta-Galactosidase staining, cell hypertrophy,...
25.
Broude E, Demidenko Z, Vivo C, Swift M, Davis B, Blagosklonny M, et al.
Cell Cycle
. 2007 Jun;
6(12):1468-71.
PMID: 17585201
Cell cycle arrest in response to DNA damage involves protein stabilization and consequent upregulation of p53, which induces transcription of cyclin-dependent kinase inhibitor p21 (CDKN1A). We now show that p21...
26.
Blagosklonny M, Demidenko Z, Giovino M, Szynal C, Donskoy E, Herrmann R, et al.
Cell Cycle
. 2006 Jul;
5(14):1574-9.
PMID: 16861892
The anti-cancer agent paclitaxel (PTX) is an effective anti-restenosis agent on drug eluting stents, primarily due to growth inhibition of coronary artery smooth muscle cells (CASMC) across a wide dose...
27.
Blagosklonny M, Trostel S, Kayastha G, Demidenko Z, Vassilev L, Romanova L, et al.
Cancer Res
. 2005 Aug;
65(16):7386-92.
PMID: 16103091
Mutant p53 is a cancer-specific target for pharmacologic intervention. We show that histone deacetylase inhibitors such as FR901228 and trichostatin A completely depleted mutant p53 in cancer cell lines. This...
28.
Demidenko Z, Halicka D, Kunicki J, McCubrey J, Darzynkiewicz Z, Blagosklonny M
Cancer Res
. 2005 May;
65(10):4401-7.
PMID: 15899832
Chemotherapy of cancer is limited by toxicity to normal cells. Drug resistance further limits the therapy. Here, we investigated selective killing of drug-resistant cancer cells by antagonistic drug combinations, which...
29.
Demidenko Z, Rapisarda A, Garayoa M, Giannakakou P, Melillo G, Blagosklonny M
Oncogene
. 2005 May;
24(30):4829-38.
PMID: 15897903
In the presence of oxygen and iron, hypoxia-inducible factor (HIF-1alpha) is rapidly degraded via the prolyl hydroxylases (PHD)/VHL pathways. Given striking similarities between p53 and HIF-1alpha regulation, we previously suggested...
30.
Demidenko Z, An W, Lee J, Romanova L, McCubrey J, Blagosklonny M
Cancer Biol Ther
. 2005 Apr;
4(4):484-90.
PMID: 15846067
By activating anti-apoptotic factors (e.g., Hsp70, Raf-1, Bcl-xL), Bcr-Abl blocks apoptotic pathways at multiple levels, thus rendering leukemia cells resistant to chemotherapeutic agents such as doxorubicin (DOX). In Bcr-Abl-transfected HL60...